The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
MPN Workshop of the Carolinas 2024 | Selecting patients with MPNs for stem cell transplantation
Uday Popat, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, briefly discusses how community physicians should select patients with myeloproliferative neoplasms (MPNs) for stem cell transplantation (SCT). Those identified as having intermediate- or high-risk using a standard scoring system will likely be candidates for SCT. This interview took place at the 1st Annual MPN Workshop of the Carolinas in Asheville, NC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So typically they could use one of the standard scoring systems that is available the IPSS+ or the IPSS, or whichever one they have access to.
And really, any person with intermediate- or high-risk disease is a transplant candidate. Even younger patients with intermediate one risk disease who have high-risk mutations or who are transfusion dependent also become candidates for transplant...
So typically they could use one of the standard scoring systems that is available the IPSS+ or the IPSS, or whichever one they have access to.
And really, any person with intermediate- or high-risk disease is a transplant candidate. Even younger patients with intermediate one risk disease who have high-risk mutations or who are transfusion dependent also become candidates for transplant.
I think what they need to keep in mind is, if they are in doubt, they should send them for transplant evaluation and let the transplant team decide whether that is a suitable patient or not.
Read more...
